Discovery of Novel Allosteric EGFR L858R Inhibitors for the Treatment of Non-Small-Cell Lung Cancer as a Single Agent or in Combination with Osimertinib-Reference-Cited by-同舟云学术

Discovery of Novel Allosteric EGFR L858R Inhibitors for the Treatment of Non-Small-Cell Lung Cancer as a Single Agent or in Combination with Osimertinib

Published:2022-09-30 Issue:19 Volume:65 Page:13052-13073
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Obst-Sander Ulrike¹,Ricci Antonio¹,Kuhn Bernd¹^ORCID,Friess Thomas²,Koldewey Philipp¹,Kuglstatter Andreas¹,Hewings David¹^ORCID,Goergler Annick¹,Steiner Sandra¹,Rueher Daniel¹,Imhoff Marie-Paule¹,Raschetti Noemi¹,Marty Hans-Peter¹,Dietzig Aline³,Rynn Caroline⁴,Ehler Andreas¹,Burger Dominique¹,Kornacker Martin⁵,Schaffland Jeannine Petrig¹,Herting Frank²,Pao William⁶,Bischoff James R.³,Martoglio Bruno³,Alice Nagel Yvonne³^ORCID,Jaeschke Georg¹^ORCID

Affiliation:

1. F. Hoffmann-La Roche Ltd, Roche Pharmaceutical Research and Early Development, Therapeutic Modalities, Roche Innovation Center Basel, Grenzacherstrasse 124, Basel4070, Switzerland

2. F. Hoffmann-La Roche Ltd, Roche Pharmaceutical Research and Early Development, Discovery Oncology, Roche Innovation Center Munich, Roche Diagnostics GmbH, Nonnenwald 2, Penzberg82377, Germany

3. F. Hoffmann-La Roche Ltd, Roche Pharmaceutical Research and Early Development, Cancer Targeted Therapies, Roche Innovation Center Basel, Grenzacherstrasse 124, Basel4070, Switzerland

4. F. Hoffmann-La Roche Ltd, Roche Pharmaceutical Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, Grenzacherstrasse 124, Basel4070, Switzerland

5. F. Hoffmann-La Roche Ltd, Roche Pharmaceutical Research and Early Development, Clinical Development Oncology, Roche Innovation Center Basel, Grenzacherstrasse 124, Basel4070, Switzerland

6. F. Hoffmann-La Roche Ltd, Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Grenzacherstrasse 124, Basel4070, Switzerland

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.2c00893

Reference34 articles.

1. Lung Cancer

2. Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship

3. Incidence of EGFR Exon 19 Deletions and L858R in Tumor Specimens From Men and Cigarette Smokers With Lung Adenocarcinomas

4. A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non–Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER)

5. Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inverted Sandwich-Type e-LCR Aided by Lambda Exonuclease-RecJf Combination Enables Ultrasensitive Detection of Low-Frequency EGFR-L858R Mutation in NSCLC;Analytical Chemistry;2024-08-06

2. Research Advances of Small Molecule EGFR-TKIs in NSCLC;Pharmacy Information;2024

3. TEFDTA: a transformer encoder and fingerprint representation combined prediction method for bonded and non-bonded drug–target affinities;Bioinformatics;2023-12-23

4. Pitfalls and Considerations in Determining the Potency and Mutant Selectivity of Covalent Epidermal Growth Factor Receptor Inhibitors;Journal of Medicinal Chemistry;2023-12-22

5. A Constitutive EGFR Kinase Dimer to Study Inhibitor Pharmacology;Molecular Pharmacology;2023-12-08